Hormone Drug Slows Prostate Cancer Growth

By Peter Geschek: Zytiga In its first full year on the market, in 2012, Johnson & Johnson's prostate cancer medicine Zytiga generated $961 million in revenues which make it a "near blockbuster". (A drug is considered blockbuster above $1 billion in sales).Zytiga is the most successful oral oncology drug launch in history. It is now approved in 65 countries and helped a huge number of men everywhere.

By The Burrill Report: By Vinay Singh Johnson & Johnson (JNJ) released interim data from a late-stage study that showed its prostate cancer drug, Zytiga, improved survival of men with less advanced forms of the disease. The newly released data may help expand the indication of the already approved drug to treat a larger patient pool.

ByEmerging Equities:These are exciting times for Johnson & Johnson (JNJ) with FDA product approvals setting the stage for higher growth. Recently the FDA approved Johnson & Johnson's drugs Zytiga for prostrate cancer, Invokana for type 2 diabetes, and Invega for schizophrenia.

By The Swiss Trader:Cancer treatment advances in the last decade have been significant and offer more hope in curing the disease than in any other point in our history. ASCO 2012 was buzzing with clinical data from the immunotherapy approach to fighting the disease as made famous by Dendreon's Provenge in 2010 - the first FDA-approved vaccine for fighting cancer.

New data on the prostate cancer drug Zytiga show it slows tumor growth and may improve survival.

By Theodore Cohen:The 2013 Genitourinary ("2013 GU") Cancers Symposium, A Transformative Multidisciplinary Approach, to be held 14-16 February, 2013, includes multiple poster sessions on Dendreon's (DNDN) Provenge (sipuleucel-T) that will be of major interest to the medical community in general and practitioners treating prostate cancer in particular.

J&J's new drug Zytiga improved survival in a clinical trial of men with prostate cancer who hadn't undergone chemotherapy—potentially supporting the drug's use earlier in the treatment cycle.